Please enable Javascript
SNMMI 2022 Meeting
In-depth coverage of the SNMMI 2022 Meeting
Study: Androgen Deprivation Therapy Does Not Affect Performance of Piflufolastat F 18-PET/CT
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
Piflufolastat F 18 is a radiopharmaceutical that targets the prostate-specific membrane antigen during imaging.
Cross-Training Healthcare Clinicians and Technicians Can Help Alleviate Staffing Shortages
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
This model assigns workers to additional or alternate roles that match existing skills and providing proper re-training.
68Ga-PSMA PET/CT Improves Prostate Cancer Diagnosis Compared With Multiparametric MRI
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
Researchers retrospectively analyzed patients who had received both 68Ga-PSMA PET/CT and mpMRI testing.
New PET Imaging Agent Can Predict Response to CAR T-Cell Therapy
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
The approach may help inform clinical decision-making early in treatment.
PSMA PET Research Supports Updates to Guidelines for Prostate Cancer Treatment
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
Updates may be needed to guidelines for salvage radiation treatments in patients with local recurrence of prostate cancer.
Be Aware of Threats to Data Integrity in Medical Imaging
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
Developers and users must be aware of the potential for data attacks and manipulation when considering AI models for imaging.
Phase 2 Study Supports Radionuclide Alpha Therapy in Patients With Advanced Neuroendocrine Tumors
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Study: New AI Scan Strategy Can Cut Radiation Exposure in Half
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to patients.
Study Supports Combination of PSMA and GRP-R-PET for Prostate Cancer Staging
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
Researchers conducted a prospective phase 2 imaging study to compare PSMA and GRP-R-targeted imaging during initial staging.
Guided Imagery Can Reduce Stress for Patients and Providers in Nuclear Medicine and Radiology Departments
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
Guided imagery can enhance coping, reduce anxiety, and decrease heart rate, respirations, and blood pressure.
Quantitative Parametric Imaging Improves Prostate Cancer Lesion Detection
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
A study explore values of parametric Ki imaging in total-body 68Ga-PSMA-11 PET/CT in patients with prostate cancer.
SNMMI Task Force Outlines Key Opportunities, Challenges, and Considerations in Artificial Intelligence
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
The framework emphasizes the importance of establishing trust among stakeholders.
PET/CT Effective in Post-COVID Evaluation and Monitoring
Kerri Fitzgerald
SNMMI 2022 Meeting
|
November 11, 2022
The study is the first to show that lingering COVID-19 symptoms can be attributed to ongoing lung inflammation.
Assessing Different Imaging Modalities in Cancer
Robert Dillard
Journal
|
November 11, 2022
During an SNMMI Annual Meeting scientific session, researchers discussed imaging modalities to diagnose different cancers.
Advertisement
Advertisement
Advertisement
Advertisement